by marcbacon | Dec 9, 2020
E. Leahy, M. Varney and D. Brunner SEP-363856, a novel, first-in-class drug treatment being developed by Sunovion Pharmaceuticals, showed robust therapeutic effects in patients diagnosed with schizophrenia across a broad range of disabling symptoms including positive,...
by marcbacon | Oct 8, 2020
Theilmann, et. al, Neuropharmacology. 2020 Theilmann, W, Gericke, B,Schidlitzki, A, Anjum, S, Borsdorf, S, Harries, T, Roberds, S.L.,Aguiar, D, Brunner, D, Leiser, S, Song, D, Fabbro, D, Hillmann, P, Wymann, M, Loscher, W.Neuropharmacology....
by marcbacon | Aug 24, 2020
DOI: 10.3233/JHD-190389 Afshin Ghavami 1, Michael Olsen 1, Mei Kwan 1, Jose Beltran 1, John Shea 1, Sylvie Ramboz 1, Wenzhen Duan 2, Daniel Lavery 3, David Howland 3, Larry...
by marcbacon | Aug 16, 2020
Kabitzke, P, Morales, D, He, D, Cox, K, Sutphen, J, Thiede, L, Sabath, E, Hanania, T, Biemans, B, Brunner, D. Genes, Brain and Behavior. 2020;e12676. DOI: 10.1111/gbb.12676 Phenotyping mouse model systems of human disease has proven to be a difficult task, with...
by marcbacon | Apr 15, 2020
Abstract Over the last two decades, awareness of the negative repercussions of flaws in the planning, conduct and reporting of preclinical research involving experimental animals has been growing. Several initiatives have set out to increase transparency and internal...
